Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to $13.8 million.

  • Cumberland Pharmaceuticals' Accounts Payables rose 1471.91% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 1471.91%. This contributed to the annual value of $13.9 million for FY2024, which is 87.88% down from last year.
  • As of Q3 2025, Cumberland Pharmaceuticals' Accounts Payables stood at $13.8 million, which was up 1471.91% from $13.4 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Accounts Payables high stood at $14.0 million for Q4 2023, and its period low was $9.0 million during Q2 2021.
  • Its 5-year average for Accounts Payables is $11.7 million, with a median of $11.4 million in 2022.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Accounts Payables tumbled by 2803.24% in 2021 and then surged by 2974.97% in 2023.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Accounts Payables stood at $9.6 million in 2021, then grew by 12.22% to $10.8 million in 2022, then grew by 29.75% to $14.0 million in 2023, then dropped by 0.88% to $13.9 million in 2024, then dropped by 0.59% to $13.8 million in 2025.
  • Its Accounts Payables stands at $13.8 million for Q3 2025, versus $13.4 million for Q2 2025 and $13.9 million for Q1 2025.